Hanoi (VNA) – The Prime Minister has decided to useover 8.8 billion VND from the national COVID-19 vaccine fund to support thefirst and second phase of clinical trials of COVIVAC vaccine, which has been developedby the Health Ministry’s Institute of Vaccines and MedicalBiologicals (IVAC) since May 2020.
COVIVAC uses viral vector technology on primarychicken embryo cell culture - a technique IVAC used previously to successfullyproduce seasonal flu vaccines. It is preserved at temperatures from 2-8 degreesCelsius.
In the first phase, it was evaluated as safe,well-tolerant and immunogenic.
The second phase will be carried out in Vu Thu district, northern ThaiBinh province, with 375 volunteers.
COVIVAC is the second “made-in-Vietnam” vaccine to be allowedfor clinical trials by the Health Ministry, following Nanogen company’sNanoCovax./.
